UK: Drug Bust-Up Reveals Hazards Of Complex Contracts

Last Updated: 14 August 2017
Article by ICSA  

A clash in court between two pharmaceutical giants highlights the importance of consistency and clarity in legal documents, says Paul Harris of Venner Shipley.

It seems the financial meltdown, which occurred in 2008 and led to austerity measures being imposed worldwide, has reached the pharmaceutical sector.

In the case of Astex Therapeutics Ltd v AstraZeneca AB (2017), Mr Justice Arnold considered AstraZeneca's decision to seek to claw back several million dollars it had paid to Astex Therapeutics.

To be able to decide this meant he had to consider the terms of a research and collaboration agreement in relation to the search for drugs to inhibit Alzheimer's disease.

With many collaborations in the pharmaceutical field, the large companies have the cash, but less ability to research specific drug applications, whereas the small research companies (often university spin-outs) have the skill and expertise, but not the cash.

So, when a dispute like this happens, the commentators tend to reach for the 'David and Goliath' metaphor. This may once have applied in this case.

However, Astex was bought by the Japanese group, Otsuka, which has a group turnover of Ł7 billion, so it is more a case of David plus his gigantic brother versus Goliath, who is not looking so big after all.

Milestone payments

The collaboration agreement was for just over two years, commencing in February 2003, after which AstraZeneca could continue researching the fruits of the collaboration by itself, which it did in its Swedish centre.

That subsequent research identified two compounds, called CD1 and CD2 in this case, as possibilities. AstraZeneca nominated these as 'candidate drugs', as a result of which a milestone payment was paid to Astex.

Although CD1 failed at the first hurdle, CD2 is currently in the final, phase III, stage of a clinical trial.

Shortly before the phase III trials, AstraZeneca wrote to Astex and stated that contrary to its earlier view, neither CD1 nor CD2 fell within the definition of the agreement (in other words, were not collaboration compounds) upon which they were obliged to pay further milestone payments.

In essence, despite AstraZeneca's own conduct in considering that a milestone payment was to be paid, the issue was whether AstraZeneca could get its money back.

"This is more a case of David plus his gigantic brother versus Goliath, who is not looking so big after all"

For those of you with knowledge of contract law, this is not on the basis of a mistake leading to the rescission of a contract, but rather a question of fact as to whether CD1 and CD2 fell within the definition of 'collaboration compounds', and there had been enrichment as a result of that mistake.

The behaviour and conduct of the parties had no bearing in this particular matter. In order for the milestone payment to become due, the compound had to be a 'hit' or a 'lead', after which AstraZeneca had to nominate the collaboration compound as a CD, and it nominated CD1 and CD2.

Million-dollar bills

Once those milestone payments had been paid, and the compound was on a path to clinical trials, the subsequent payments became eye-wateringly large, from $1 million up to $5 million at the start of the phase III clinical trial.

Hence, AstraZeneca reconsidered whether any of the compounds actually fell within the definition. The collaboration agreement was 67 pages long, detailed the research steps and specific project concerned, and was regarded by the judge as extremely complex.

In 2009, the parties executed an amendment agreement altering some of the terms of the agreement. The key provision, clause 2.3, provided that the collaboration agreement had expired and all the hits, leads and CDs had been agreed by the parties and were attached as a schedule. That schedule was 127 pages long and contained 1,335 compounds.


The trial lasted 13 days, involved 16 witnesses of fact, and one expert on each side. The decision is 90 pages long.

In his judgment, the judge skips lightly across the technical background to Alzheimer's disease and possible inhibitors, but only because he had previously set it out in a judgement of his in 2013, which was itself another 90-page blockbuster.

The next large chunk of text delved into the world of drug discovery. The only part of his judgment that was brief dealt with the law and approach to the construction of the agreement, a now well-trodden path.

The difficulty faced with increasingly lengthy and complex contracts is that the chances of provisions seemingly contradicting themselves increases.

This was apparent in the first part decided by the judge when he considered whether the project could have been carried on by AstraZeneca after the collaboration term ended.

Although he considered both yes and no answers were possible, the ambiguities of the drafting tipped the balance in favour of AstraZeneca.

"There is no point in lawyers drafting intricate agreements if those they serve have no idea how to interpret them"

The significance of the finding of the judge was that it invited the question of whether CD2 resulted from the programme or arose out of the work AstraZeneca did on its own.

However, having analysed the actual situation, as he saw it, and what was defined as a 'collaboration compound' (in some 40 pages of judgment), the judge concluded that neither CD1 nor CD2 fell within the definition.

Financial recovery

The final part of the judgment considered whether AstraZeneca, having accepted by its own conduct that payment was due, and paying it, could nevertheless recover its money. This is called 'a claim to restitution of an enrichment' that can only be invoked where:

  • At the time the enrichment was conferred the payer was mistaken
  • The mistake caused the enrichment to occur and, but for the mistake, the enrichment would not have occurred.

The main evidence, oddly enough, came from AstraZeneca's own former vice-president. Surprisingly, he gave evidence on behalf of Astex, in which he reiterated his firm belief that CD1 was a collaboration compound.

The judge carefully reviewed the process that was followed by those witnesses who made the recommendation that the milestone payment for CD1 should be paid. This turned out to be the former vice-president himself.

The judge pointed out that the witness was undoubtedly mistaken at the relevant time, not least because he still believed CD1 was a collaboration compound when, as a fact, the judge concluded it could not be. So, he was still mistaken, even after judgment.

As for the payment for CD2, it transpires that because of what happened in respect of CD1, the finance department of AstraZeneca merely followed suit because there was no reason to consider that CD2 was to be dealt with any differently to CD1, for which a milestone payment had already been made.

Therefore, AstraZeneca was able to recover the money it had paid.

This case highlights the importance of consistency and clarity in legal documents. Even here, in an agreement 67 pages long, there are still errors in drafting.

However, it is not the error in drafting that ultimately caused the problem, it was the error in legal construction as to whether something did or did not fall within the definition of 'collaboration compound' – and thus whether or not a payment was necessary.

The salutary lesson here is there is no point in clever lawyers drafting lengthy, intricate agreements if those operating under them have no real idea how to interpret the drafting.

Paul Harris is a Partner of Venner Shipley

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.